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The Malaria Policy Advisory Committee to the World Health Organization (WHO) held its fifth meeting in Geneva,
Switzerland from 12 to 14 March 2014. This article provides a summary of the discussions, conclusions and
recommendations from that meeting.
Meeting sessions covered: maintaining universal coverage of long-lasting insecticidal nets; combining indoor
residual spraying with long-lasting insecticidal nets; the sound management of old long-lasting insecticidal nets;
malaria diagnosis in low transmission settings; the Global Technical Strategy for Malaria (2016 -2025); and Technical
Expert Group updates on vector control, the RTS,S vaccine, the Malaria Treatment Guidelines, anti-malarial drug
resistance and containment, and surveillance, monitoring and evaluation.
Policy statements, position statements, and guidelines that arise from the Malaria Policy Advisory Committee
meeting conclusions and recommendations will be formally issued and disseminated to WHO Member States by
the WHO Global Malaria Programme.
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The Malaria Policy Advisory Committee (MPAC) to the
World Health Organization (WHO) held its fifth meeting
from 12 to 14 March 2014 in Geneva, Switzerland, follow-
ing its meetings in February and September 2012, and
March and September 2013 [1-4]. This article provides a
summary of the discussions, conclusions and recommenda-
tions from that meeting as part of the Malaria Journal
thematic series “WHO global malaria recommendations” [5].
The following sections of this article provide details
and references for the background documents presented
at the open sessions of the committee on: maintaining
universal coverage of long-lasting insecticidal nets; com-
bining indoor residual spraying with long-lasting insecti-
cidal nets; the sound management of old long-lasting
insecticidal nets; malaria diagnosis in low transmission
settings; the Global Technical Strategy for Malaria (2016
-2025); and Technical Expert Group (TEG) updates on* Correspondence: mpacgmp@who.int
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made available in this article, unless otherwisevector control, the RTS,S vaccine, the Malaria Treatment
Guidelines, anti-malarial drug resistance and contain-
ment, and surveillance, monitoring and evaluation.
The MPAC discussion and recommendations related
to these topics, which took place partially in closed ses-
sion, are also included. MPAC decisions are reached by
consensus [6]. The complete set of all MPAC meeting-
related documents including background papers, presen-
tations, and member declarations of interest can be
found online on the MPAC website [7]. The next meet-
ing of the MPAC will be 10 to 12 September 2014 [7].Report from the WHO global malaria programme
The acting Director of the WHO Global Malaria
Programme (WHO-GMP) updated MPAC members on
the major publications from WHO-GMP since its last
meeting, including ‘Eliminating malaria: The long road
to malaria elimination in Turkey’ [8], ‘Malaria control in
humanitarian emergencies: an inter-agency field hand-
book’ [9], ‘Epidemiological approach for malaria control
training manuals’ [10], and ‘WHO informal consultationee and Secretariat; licensee BioMed Central Ltd. This is an Open Access article
mmons Attribution License (http://creativecommons.org/licenses/by/4.0), which
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A global review of evidence and practice’ [11].
The most significant of these recent publications is the
World Malaria Report 2013 [12] which was launched in
December in Washington DC. Among the highlights of
the report are the following:
1. 59 out of 103 countries that had ongoing malaria
transmission in 2000 are meeting the MDG target of
reversing the incidence of malaria.
2. 52 of these are on track to meet Roll Back Malaria
(RBM) and World Health Assembly targets of
reducing malaria case incidence rates by 75% by
2015, including 8 countries in the WHO African
Region.
3. In 41 countries, which account for 80% of all
malaria cases, poor data quality or inconsistency in
reporting methods makes it impossible to assess
trends using reported data.
4. Between 2000 and 2012, estimated malaria mortality
rates fell by 42% globally in all age groups and by
48% in children <5 years old.
5. Malaria mortality rates are projected to decrease by
52% in all ages, and by 60% in children under
5 years of age by 2015.
6. An estimated 3.3 million malaria deaths were
averted between 2001 and 2012, and 69% of these
lives saved were in the 10 countries with the highest
malaria burden in 2000 - progress is being made
where it matters.
7. About 3 million (90%) of the deaths averted between
2001 and 2012 are estimated to be in children under
five years of age in sub-Saharan Africa. These
account for 20% of the 15 million child deaths that
are estimated to have been averted globally since
2000 through overall reductions in child mortality
rates. Thus, decreases in malaria deaths have
contributed substantially to progress towards
achieving the target for MDG 4.
8. In 2012, financing of malaria programmes was
estimated to be less than half of the estimated US$
5.1 billion required globally.
9. Despite substantial progress in scaling-up programmes,
40% of households in sub-Saharan Africa did
not have access to a single insecticide-treated net
(ITN) in 2012 and millions still do not have
access to diagnostic testing and artemisinin-based
combination therapy (ACT).
10. As a result, an estimated 207 million cases
(uncertainty interval, 135–287 million) and 627,000
malaria deaths (uncertainty interval, 473,000–789,000)
are estimated to have occurred in 2012.
11. There is an urgent need to increase funding for
malaria control and to expand programmecoverage, in order to meet international targets for
reducing malaria cases and deaths.
A full copy of the World Malaria Report 2013 is
available on the WHO-GMP website [12].
MPAC commended the work of WHO-GMP and its
partners in the global malaria community in supporting
countries in their efforts to monitor and reduce their
malaria burden. The next report from WHO-GMP to
MPAC in September 2014 will include updates from
each of the WHO regions. It is anticipated that the new
director of WHO-GMP will be recruited and announced,
and ideally be in post, by that time.
Maintaining universal coverage of long-lasting insecticidal
nets
The Vector Control TEG (VC TEG) met for the second
time from 24-26 February 2014 with three major outputs
presented to MPAC. The first was draft recommenda-
tions for countries facing short-term gaps in long-lasting
insecticidal net (LLIN) coverage. These draft recommen-
dations were discussed at length but were ultimately not
endorsed. While MPAC members acknowledged that
projected funding shortfalls in some countries indicate
the potential for temporary gaps in LLIN coverage, they
were concerned that recommending a strategy of priori-
tized LLIN allocation might be misinterpreted as a move
away from the goal of LLIN universal coverage. The pro-
posed strategy could confuse Member States and detract
from the principal task for ministries of health and their
donors and partners, which is to secure sufficient re-
sources to ensure universal coverage. These concerns
were echoed during the meeting’s closed session. Instead
MPAC recommended that WHO reiterate the goal of
LLIN universal coverage in line with the outcomes from
the September 2013 meeting [13]. In that previous rec-
ommendation, WHO outlined how universal coverage,
defined as universal access to and use of LLINs, can be
achieved and sustained operationally.
MPAC also suggested updating the universal coverage
of LLINs recommendation in order to address confusion
regarding LLIN procurement quantifications for mass
campaigns. They suggested that calculation of the LLINs
needed should be adjusted when quantifying at the popu-
lation level, since many households have an odd number
of members. Therefore, WHO should reiterate its rec-
ommendation that for procurement purposes (versus
estimating population access, which is a different matter)
countries should use an overall ratio of 1 LLIN for every
1.8 persons in the target population. Additional informa-
tion, and the rationale behind the clarification, is provided
in the note ‘Estimating population access to ITNs versus
quantifying for procurement for mass campaigns’ which is
now available on the WHO-GMP website [14].
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insecticidal nets
Guidance for countries on combining indoor residual
spraying (IRS) and LLINs was also presented by the VC
TEG [15]. The reduction in disease burden of malaria in
recent years has in a substantial part been attributed to
the massive scale up of these two main vector control
interventions, particularly in Africa south of the Sahara.
A number of countries have deployed the two interven-
tions in combination in an attempt to reduce transmis-
sion further; however, this action has not been informed
by clear evidence.
Based on a review of published and unpublished clus-
ter randomized trials conducted in Benin, Tanzania, The
Gambia and Sudan, the VC TEG presented a summary
of evidence on the combined use of IRS and LLINs
which was reviewed and endorsed by MPAC following
edits to improve order and clarity [16]. The main con-
clusions are summarized below:
1. In settings where there is high coverage with LLINs
and they remain effective, IRS may have limited
utility in reducing malaria morbidity and mortality.
However, IRS may be implemented in areas where
LLINs are being used as part of an insecticide
resistance management strategy [17].
2. If LLINs and IRS are to be deployed together in
the same geographical location for management
of insecticide resistance, the IRS should use
non-pyrethroid insecticides.
3. Malaria control and elimination programmes should
prioritize delivering either LLINs or IRS at high
coverage and to a high standard rather than
introducing the second intervention as a means of
compensating for deficiencies in the implementation
of the first.
4. More evidence is needed on the effectiveness of
combining IRS and LLIN in both high and low
transmission settings. Evidence is also needed
from different eco-epidemiological settings
outside Africa.
5. All programmes in any transmission setting that
invest in the combined use of LLINs and IRS should
include a rigorous programme of monitoring and
evaluation to determine whether the additional
inputs have the desired impact. Countries that are
already using both interventions should similarly
undertake an evaluation of the effectiveness of the
combination versus either LLINs or IRS alone.
A full copy of the VC TEG report, including the full
review and summary of evidence, is available on the
WHO-GMP website, in addition to the published WHO
guidance note [16].Sound management of old long-lasting insecticidal nets
The final major VC TEG output presented to MPAC
was ‘Recommendation on the sound management of old
LLINs’ [18]. The VC TEG drew attention to this import-
ant issue because between 2004 and 2013, public health
programmes distributed more than 700 million conven-
tional ITNs and LLINs to communities. Currently,
LLINs and the vast majority of their packaging (encom-
passing bags and baling materials) are made of non-
biodegradable plastic material. However, most endemic
countries do not currently have the resources for collec-
tion and waste disposal for these materials. The large-
scale deployment of LLINs has given rise to questions
on the most appropriate and cost-effective way to deal
with the plastic waste that is accumulating in communi-
ties, particularly in countries where the malaria burden
is high and where ministries of health seek to reach or
sustain universal coverage of LLINs.
In summary, the VC TEG recommended that:
1. Residents should be advised through appropriate
communication strategies to continue to use LLINs
– even if they have holes – until another LLIN in
better condition is available to replace it.
2. Residents should also be advised not to dispose of
old LLINs (defined as those no longer used within
households for the purpose of protecting individuals
against malaria) in any water body, as the residual
insecticide on the net can be toxic to aquatic
organisms and especially to fish.
3. National malaria control and elimination
programmes should only collect old LLINs if it
has been ensured that: (a) communities are not
left uncovered i.e. new LLINs are distributed to
replace old ones, and (b) there is a suitable and
sustainable plan in place for safe disposal of the
collected material.
4. The collection of old LLINs should not divert the
efforts and attention of malaria programmes away
from their core duties, including the task of
maintaining universal coverage.
5. If LLINs and their packaging are collected, the
best option for their disposal is high-temperature
incineration. They should not be burned in the
open air. In the absence of such facilities, the
recommended method of disposal is burial. Burial
should be away from water sources and preferably in
non-permeable soil, in line with ‘Recommendations
on the sound management of packaging for long
lasting insecticidal nets’ [19].
6. National malaria control and elimination
programmes should work with national environment
authorities to ensure that the information and
recommendations in the recommendation are taken
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and regulations.
MPAC fully endorsed the VC TEG’s recommenda-
tions for the sound management of old LLINs, follow-
ing discussion on how to improve the wording of the
recommendations so that they would not unintention-
ally lead to a diversion of resources or responsibility.
These changes are reflected in the summary above. The
recommendations were approved pending edits by the
WHO Secretariat to improve the clarity of the docu-
ment prior to publication. The WHO recommendations
for the sound management of old LLINs, including
further details on the background and evidence base for
the recommendations, are now available on the WHO-
GMP website [20].
Malaria diagnosis in low transmission settings
In recent years, the application of nucleic acid amplifica-
tion (NAA)-based diagnostic tools to detect malaria for
epidemiological surveys and research has increased sig-
nificantly. Many different NAA assays are available with
greater sensitivity than microscopy and rapid diagnostic
tests (RDTs). NAA is the method of choice for confirm-
ing Plasmodium knowlesi and other zoonotic malaria
infections.
In order to develop recommendations on the role of
molecular diagnostic tests for malaria in low transmis-
sion areas, WHO/GMP convened an Evidence Review
Group (ERG) on 16-18 December 2013 with the follow-
ing objectives: (a) review current knowledge on the
contribution of sub-microscopic parasitaemia to malaria
transmission, particularly in areas with low transmission;
(b) review the diagnostic performance, technical and
resource requirements of available NAA methods for
detecting low-density infections and to recommend the
most suitable methods for population surveys and active
case investigations; (c) review requirements to ensure
quality for NAA methods and to build capacity to sup-
port their use in pre-elimination and elimination set-
tings; (d) revise the current WHO recommendations for
malaria diagnostic approaches in low transmission set-
tings; and (e) discuss the malaria diagnostic research and
development pipeline and reach consensus on preferred
product characteristics for new diagnostic tools to meet
public health needs for malaria elimination.
Based on the conclusions of the ERG [21], the MPAC
endorsed the following recommendations [22]:
1. Quality-assured RDT and microscopy are the
primary diagnostic tools for the confirmation and
management of suspected cases of clinical malaria in
all epidemiological situations, including areas of low
transmission, due to their high diagnosticperformance in detecting clinical malaria, their wide
availability and relatively low cost. Similarly, RDT
and microscopy are appropriate tools for routine
malaria surveillance (of clinical cases) in the
majority of malaria-endemic settings.
2. A number of NAA techniques are available and are
more sensitive in detection of malaria compared to
RDTs and microscopy. Generally, the use of more
sensitive diagnostic tools should be considered only
in low transmission settings where there is already
widespread implementation of malaria diagnostic
testing and treatment and low parasite prevalence
rates (e.g. < 10%). Use of NAA-based methods
should not divert resources away from malaria
prevention and control interventions and
strengthening of the health care services,
including the surveillance system.
3. Submicroscopic Plasmodium falciparum and
Plasmodium vivax infections are common in low as
well as in high transmission settings. The use of
NAA methods by malaria programs should be
considered for epidemiological research and surveys
aimed at mapping submicroscopic infections at low
transmission intensity. There may also be a use for
NAA methods for identifying foci for special
intervention measures in elimination settings.
4. The majority of infections with asexual parasites
have gametocytes detectable by molecular
amplification methods, at low density not detectable
by microscopy or RDTs. Most malaria infections
(microscopic and submicroscopic) should be
considered as potentially infectious and able to
contribute to ongoing transmission. There is no
need for routine detection of gametocytes using
sensitive mRNA amplification methods in malaria
surveys or clinical settings.
5. Common standards for nucleic acid based assays
should be developed, including use of the WHO
International P. falciparum DNA Standard for NAA
assays and development of standards for other
Plasmodium species, particularly P. vivax should be
undertaken. A standard operating procedure should
be developed which defines methods for sample
collection, extraction, and the recommended
equivalent quantity of blood to be added to the
assay. Development of an international, external
quality assurance system is strongly recommended
to ensure that data obtained from NAAs are reliable
and comparable.
6. In order to establish the role of serological assays in
epidemiological assessments, there is a need for
standardization and validation of reagents (antigens
and controls), assay methodologies and analytical
approaches.
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report, which is available in its entirety on the WHO-
GMP website [23].
Global technical strategy for malaria (2016 - 2025)
Following an expression of support by WHO Member
States at the 2013 World Health Assembly in May last
year, WHO-GMP is coordinating the development of the
Global Technical Strategy for Malaria (GTS) for 2016-
2025. Under the guidance of MPAC, the GTS will articu-
late the vision and goals for malaria over the next decade
and bring together current policy recommendations
in a comprehensive, evidence-based strategy for WHO
Member States to use in developing their own strategies,
wherever they are along the pathway to elimination.
Concurrent with the development of the GTS, the Roll
Back Malaria (RBM) Partnership is coordinating the de-
velopment of the Global Malaria Action Plan 2 (GMAP2)
[24]. The GMAP2 will support the implementation of the
GTS through global advocacy, resource mobilization, part-
ner harmonization, the engagement of non-health sectors,
as well as global, regional and country-level planning. Both
documents are being developed in a synchronous, collab-
orative process, involving an overlap in steering commit-
tees, and will be jointly launched in 2015 to provide a
strengthened platform for continuing malaria investments
in the broader post-2015 development agenda.
The Chair of the GTS Steering Committee updated
MPAC on the process to date [25], and provided the
background on the proposed GTS targets [26], the over-
arching themes of the GTS and the pathway to elimin-
ation [27]. The GTS is being developed through an
inclusive, country-driven approach. Based on a founda-
tion of existing strategies, it will include input from con-
sultations with WHO Regions, international experts, and
country programmes. A series of regional consultations
is scheduled between March and June 2014 and a public
web consultation is scheduled for July.
MPAC members, and those observers present at the
meeting, reviewed the first draft of the GTS and pro-
vided comments for the GTS Steering Committee and
WHO-GMP Secretariat to consider prior to the start of
the regional consultations. This discussion was further
enriched via breakout groups and more detailed feed-
back on each of the GTS’s strategic directions.
WHO-GMP also provided MPAC with an update on pro-
gress of the technical brief on P. vivax malaria, which will
consolidate all P. vivax-specific guidance into one docu-
ment for the first time [28]. Based on the feedback from
MPAC, the schedule for developing the P. vivax brief was
modified so that it is aligned with the timeline for the GTS
to facilitate the inclusion of relevant P. vivax guidance.
MPAC commended the GTS Steering Committee and
WHO-GMP on progress to date, and the leadership ofWHO-GMP and RBM on the close alignment of the
processes for the GTS and GMAP2. MPAC members
were especially supportive of the inclusive process that
will involve country and regional input; these will be
central to the development of both the GTS and the
P. vivax brief, and critical to success. They acknowl-
edged that as with any first draft of a document, greater
development of the themes and targets was needed, but
that it was useful to go into the regional consultations
with a draft to provide a foundation for discussion.
The MPAC will next review the GTS electronically
in August 2014, prior to its submission to the WHO
Executive Board in September 2014.
Updates from technical expert groups
In this session of the MPAC meeting, members received
brief updates from each of MPAC’s standing expert groups.
Vector control advisory group
This joint expert group between the WHO Neglected
Tropical Diseases Department and WHO-GMP func-
tions to review and assess the public health value and
“proof of principle” (epidemiological impact) of new
tools, approaches and technologies; and to make recom-
mendations on their use for vector control within the
context of integrated vector management in multi-
disease settings. The VCAG explained that one challenge
to its programme of work has been the distinction that
it assesses new classes of technology but is not involved
in considering individual commercial products or the
specifications of those products; this falls under the
remit of WHOPES [29]. MPAC advised that the VCAG
make its function and the process to submit a dossier
for evaluation of innovative vector control tools more
explicit on its webpage [30].
RTS,S/AS01 malaria vaccine
The Chair of the Joint Technical Expert Group (JTEG)
on malaria vaccines entering pivotal phase 3 trials and
beyond, established by the WHO Initiative for Vaccine
Research (IVR) and WHO-GMP, provided an update to
MPAC on its assessment and preparations for policy
recommendations for the RTS,S/AS01 malaria vaccine
[31]. Key analyses that are expected in 2014 include the
results from the 30 months follow-up; the effect of a
booster dose at 18 months; the effect of seasonality; and
the breakdown of efficacy by age group within the 5-17
month age range. A detailed Q&A related to the RTS,S/
AS01 vaccine is available on the JTEG webpage [32].
MPAC reiterated that RTS,S/AS01 will be evaluated as
an addition to, not a replacement for, existing prevent-
ive and treatment measures, and that it is too early
to define the potential public health role(s) of RTS,
S/AS01. Depending on the results obtained in 2014,
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make the first malaria vaccine policy recommendations
in late 2015.
WHO guidelines for the prevention and treatment
of malaria
The Co-chair of the Chemotherapy TEG updated MPAC
on progress with developing the third edition of the
WHO Guidelines for the Prevention and Treatment of
Malaria (MTGs) [33]. In brief, the process is on track;
the updated systematic reviews of existing recommenda-
tions are now complete and the TEG met to review and
reach consensus on the draft guidelines in November
2013. They will meet again in June 2014 to finalize the
draft before beginning the process of internal and exter-
nal review prior to presenting the MTGs to MPAC at its
next meeting in September 2014. The Co-chair also
presented the results of an online MTG end-user survey
whereby the majority of respondents thought the MTGs
were clearly written, appropriate in scope and size, and
practically very useful. As a result, the TEG will retain
the current MTG format for the new edition.
Drug resistance and containment
WHO-GMP updated MPAC on the latest drug resistance
surveillance data and the agenda for the Drug Resistance
and Containment (DRC) TEG meeting scheduled for
28-30 April 2014 in Geneva [34]. Although there have
been admirable efforts to slow the spread of artemisinin
resistance, efforts to contain resistance are proving to
be more challenging than anticipated. There is now
evidence for artemisinin resistant P. falciparum malaria in
Cambodia, Vietnam, Lao PDR, Thailand, and Myanmar
with independent emergence of new foci. MPAC, while
acknowledging the hard work of the DRC TEG to date,
urged it to focus much more strongly on strategies for
artemisinin resistance containment at its April meeting.
The TEG will report back to MPAC at its next meeting in
September 2014.
Surveillance, monitoring and evaluation
WHO-GMP updated MPAC on progress with imple-
menting the recommendations of the ERG on malaria
burden estimation (ERG MBE) and in constituting the
Surveillance, Monitoring and Evaluation (SME) TEG
[35]. Although the call for nominations for members
had been completed by the time of the MPAC meeting,
not all proposed members had accepted their invita-
tions and the member list was not announced. The
membership is now posted on the WHO-GMP website
[36] and their first meeting was convened from 14-16
May 2014 in Geneva. They will meet again in August
2014 and will report back to MPAC at its next meeting
in September 2014.Discussion
The wording for recommendations were finalized by
MPAC during their closed session following the two and a
half days of open sessions; conclusions have been included
in the summaries of the meeting sessions above, and links
to the full set of meeting documents are provided as refer-
ences. Position statements and policy recommendations
made by the MPAC will be issued formally and dissemi-
nated to WHO Member States by WHO-GMP or the
WHO Regional Offices. Conclusions and recommenda-
tions from MPAC meetings are published in the Malaria
Journal as part of this series.
Feedback from the MPAC meeting will also be given
to and received from the global malaria community at
the RBM Board meeting in May 2014, through the pub-
lication of this article, and subsequent correspondence.
On-going engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be
encouraged. In addition to open registration for MPAC
meetings, which will continue (via the WHO-GMP web-
site starting in July 2014) and attendance by four stand-
ing observers (RBM, the Global Fund, UNICEF, Office of
the UN Special Envoy for Financing the Health Millen-
nium Development Goals and for Malaria), the active
participation of seven rotating National Malaria Control
Programme representatives and all six WHO Regional
Malaria Advisors was strongly welcomed.
Conclusion
The meeting feedback received from participants and
observers [37], and MPAC members themselves, was very
positive. Having met five times to date, the format of
MPAC meetings and its feedback loops with other advis-
ory bodies and stakeholders is fairly settled, although it
remains an evolving process. WHO-GMP and the MPAC
continue to welcome strongly any feedback, support, and
suggestions for improvement to MPAC meetings from the
global malaria community.
The next meeting of the MPAC will take place from
10 to 12 September 2014 in Geneva, Switzerland.
Further information including the agenda and details on
how to register will be made available in July 2014 on
the MPAC page of the WHO-GMP website, although
questions are welcome at any time [7].
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